Top > Search of Japanese Patents > A novel peptide-based therapeutic compound against chronic myeloid leukemia (CML), which targets the PH domain of p210-BCR-ABL.

A novel peptide-based therapeutic compound against chronic myeloid leukemia (CML), which targets the PH domain of p210-BCR-ABL. (Patent unpublished to the public)

Patent code P190016091
File No. S2019-0065-N0
Posted date Jun 5, 2019
Application number P2018-210822
Date of filing Nov 8, 2018
Title A novel peptide-based therapeutic compound against chronic myeloid leukemia (CML), which targets the PH domain of p210-BCR-ABL. (Patent unpublished to the public)
Abstract Resistance to the widely used tyrosine kinase inhibitors (TKIs) for the CML treatment is a major problem to be solved. The present invention is a peptide-based compound that targets the PH domain of BCR-ABL, the causative gene product for CML. The compound inhibits the accumulation of damaged mitochondria and then the enhanced production of reactive oxygen species, both of which are triggered by BCR-ABL. The compound can be a novel type of therapeutic agent against CML.
(In Japanese)ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記問合せ先にご相談下さい。


PAGE TOP

close
close
close
close
close
close
close